{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:33:03Z","timestamp":1790285583692,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T00:00:00Z","timestamp":1445385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Research Council of the Northern Region of Denmark and F Hoffmann-La Roche"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>18F\u2010fluorodeoxyglucose PET\/CT (PET\/CT) is the current state\u2010of\u2010the\u2010art in the staging of diffuse large B\u2010cell lymphoma (DLBCL) and has a high sensitivity for extranodal involvement. Therefore, reassessment of extranodal involvement and the current prognostic indices in the PET\/CT era is warranted. We screened patients with newly diagnosed DLBCL seen at the academic centers of Aalborg, Copenhagen, and British Columbia for eligibility. Patients that had been staged with PET\/CT and treated with R\u2010CHOP(\u2010like) 1<jats:sup>st<\/jats:sup> line treatment were retrospectively included. In total 443 patients met the inclusion criteria. With a median follow\u2010up of 2.4 years, the 3\u2010year overall (OS) and progression\u2010free survival (PFS) were 73% and 69%, respectively. The Ann Arbor classification had no prognostic impact in itself with the exception of stage IV disease (HR 2.14 for PFS, <jats:italic>P<\/jats:italic>&lt;0.01). Extranodal involvement was associated with a worse outcome in general, and in particular for patients with involvement of &gt;2 extranodal sites, including HR 7.81 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) for PFS for &gt;3 sites. Bone\/bone marrow involvement was the most commonly involved extranodal site identified by PET\/CT (29%) and was associated with an inferior PFS and OS. The IPI, R\u2010IPI, and NCCN\u2010IPI were predictive of PFS and OS, and the two latter could identify a very good prognostic subgroup with 3\u2010year PFS and OS of 100%. PET\/CT\u2010ascertained extranodal involvement in DLBCL is common and involvement of &gt;2 extranodal sites is associated with a dismal outcome. The IPI, R\u2010IPI, and NCCN\u2010IPI predict outcome with high accuracy. Am. J. Hematol. 90:1041\u20131046, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24169","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T08:55:26Z","timestamp":1439283326000},"page":"1041-1046","source":"Crossref","is-referenced-by-count":87,"title":["Outcome prediction by extranodal involvement, IPI, R\u2010IPI, and NCCN\u2010IPI in the PET\/CT and rituximab era: A <scp>D<\/scp>anish\u2013<scp>C<\/scp>anadian study of 443 patients with diffuse\u2010large <scp>B<\/scp>\u2010cell lymphoma"],"prefix":"10.1002","volume":"90","author":[{"given":"Tarec Christoffer","family":"El\u2010Galaly","sequence":"first","affiliation":[{"name":"Department of Hematology Aalborg University Hospital Aalborg Denmark"},{"name":"Clinical Cancer Research Center, Aalborg University Hospital Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine University of British Columbia Vancouver BC Canada"},{"name":"King Saud University Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Werner","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Hematology Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Functional Imaging British Columbia Cancer Agency and the University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Nully Brown","sequence":"additional","affiliation":[{"name":"Department of Hematology Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine &amp; PET Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Aalborg University Hospital Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Erik","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Department of Hematology Aalborg University Hospital Aalborg Denmark"},{"name":"Clinical Cancer Research Center, Aalborg University Hospital Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Department of Hematology Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.7080"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.875169"},{"key":"e_1_2_5_15_1","first-page":"482","article-title":"Poition emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings M","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-473389"},{"key":"e_1_2_5_17_1","first-page":"117","article-title":"Is CT scan still necessary for staging in Hodgkin and non\u2010Hodgkin lymphoma patients in the PET\/CT era?","volume":"17","author":"Raanani P","year":"2006","journal-title":"AnnOncol"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr058"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg004"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.504872"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.01035.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.005355"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31826cebad"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2256-0"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800691"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.164"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2010.25.3.301"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111203"},{"key":"e_1_2_5_33_1","first-page":"1","article-title":"Diffuse large B\u2010cell lymphoma: Sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era","author":"Lu CS","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880005"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-2003-y"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.114710"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23730"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1353-6"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198506203122504"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13276"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24169","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:36:35Z","timestamp":1695537395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,21]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/ajh.24169"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24169","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,21]]}}}